Brolucizumab—foreseeable workflow in the current scenario

Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa; Kuppermann, Baruch D.; Bandello, Francesco; Regillo, Carl D.; Boyer, David S.; Nguyen, Quan Dong

doi:10.1038/s41433-020-01324-w

Cited by 18 publications

(31 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Таким образом, на основании результатов применения бролуцизумаба зарубежные ретинологи и Королевское общество офтальмологов рекомендуют рассматривать использование данного препарата в лечении ВМД в качестве второй-третьей линий терапии -протокол A BRAVE SAVE [42,43] (рис. 3).…”

Section: Fa Of Patient With Retinovasculitis O N T H E R E T I N a L Peripheryunclassified

“…-на каждом визите проводить тщательное обследование пациента на предмет развития у него васкулита (по рекомендациям различных сообществ при подозрении на васкулит следует проводить ФАГ, ИЦАГ, широкопольную ОКТ, ОКТА); -в случае развития васкулита прекратить лечение бролуцизумабом и провести соответствующее лечение, после чего перевести пациента на другой анти-VEGF препарат [42,43].…”

Section: Fa Of Patient With Retinovasculitis O N T H E R E T I N a L Peripheryunclassified

“…В случае же необходимости применения интракамерного или интравитреального введения антибактериальных препаратов в офтальмологической практике следует соблюдать схемы разведения лекарственного вещества для исключения развития HORV [42,43].…”

Section: Fa Of Patient With Retinovasculitis O N T H E R E T I N a L Peripheryunclassified

“…Рекомендации экспертов-ретинологов: как избежать побочного действия, связанного с бролуцизумабом, путем тщательного изучения имеющихся данных. Протокол A BRAVE SAVE[43] Fig.3. Retinologists' recommendations: Avoiding Brolucizumab Related Adverse Event by Scrutinizing Available Evidence "A BRAVE-SAVE"[43] …”

unclassified

“…Протокол A BRAVE SAVE[43] Fig.3. Retinologists' recommendations: Avoiding Brolucizumab Related Adverse Event by Scrutinizing Available Evidence "A BRAVE-SAVE"[43]…”

mentioning

confidence: 99%

See 4 more Smart Citations

Modern concept of a new group of retinal vasculitis

Лоскутов

Коврижкина

Andryuhina

2022

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Retinal vasculitis is a rare condition that occurs both in systemic severe diseases and as an adverse event of intraocular drug injections. With the emergence of new anti-VEGF drugs, a number of international authors report on the occurrence of retinal occlusive vasculitis, which led to a decrease in visual acuity. The review presents possible pathogeneses of this condition, approaches to its diagnosis and an algorithm for managing the patients with occlusive vasculitis.

show abstract

Section: Fa Of Patient With Retinovasculitis O N T H E R E T I N a L Peripheryunclassified

unclassified

“…Протокол A BRAVE SAVE[43] Fig.3. Retinologists' recommendations: Avoiding Brolucizumab Related Adverse Event by Scrutinizing Available Evidence "A BRAVE-SAVE"[43]…”

mentioning

confidence: 99%

See 3 more Smart Citations

Modern concept of a new group of retinal vasculitis

Лоскутов

Коврижкина

Andryuhina

2022

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

show abstract

Sub-Tenon’s capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation

Hikichi

2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis

Finger

Dennis²,

Freitas

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Introduction A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the comparative efficacy of brolucizumab relative to other anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) at 1 and 2 years, and overall safety and injection frequency of each treatment. Methods An SLR identifying randomized controlled trials (RCTs) published before June 2021 according to a pre-specified protocol was followed by a Bayesian NMA to compare brolucizumab (6 mg q12w/q8w) against sham and all relevant anti-VEGF regimens. Pooled mean injection frequency, serious adverse ocular events, and discontinuation rates were estimated for each treatment regimen. Results Nineteen RCTs were included in NMA base-case analysis. Brolucizumab (6 mg q12w/q8w) with loading-phase (LP) demonstrated superior best-corrected visual acuity (BCVA) gains to sham both at year 1 (mean difference 16.8 [95%CrI 13.3, 20.4]) and year 2 (mean difference 21.2 [95%CrI 17.4, 25.0]) and was comparable to other anti-VEGFs. Brolucizumab (6 mg q12w/q8w) also showed superior retinal thickness reduction to most comparators including ranibizumab (0.5 mg q4w; year 1 mean difference − 50.1 [95%CrI − 70.3, − 29.8]; year 2 mean difference − 49.5 [95%CrI − 70.8, − 28.6]), aflibercept (2 mg q8w; year 1 mean difference − 39.7 [95%CrI − 52.9, − 26.4]; year 2 mean difference − 35.0 [95%CrI − 49.1, − 21.4]), and faricimab (6 mg q16w/q8w; year 1 mean difference − 27.6 [95%CrI − 42.3, − 12.8]). Brolucizumab (6 mg q12w/q8w) showed similar rates of treatment discontinuation and serious and overall adverse events (both years). At year 2, pooled annualized injection frequency was lowest for brolucizumab (6 mg q12w/q8w) and highest for ranibizumab (0.5 mg q4w) at 5.7 and 11.5 injections annually, respectively. Conclusion Among all licensed anti-VEGF treatments, brolucizumab showed superior reduction in retinal thickness and comparable BCVA gains and discontinuation rates, despite having the lowest injection frequency. The current study provides the most up-to-date, robust comparison of treatments for nAMD. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02193-3.

show abstract

Brolucizumab—foreseeable workflow in the current scenario

Cited by 18 publications

References 8 publications

Modern concept of a new group of retinal vasculitis

Modern concept of a new group of retinal vasculitis

Sub-Tenon’s capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation

Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis

Contact Info

Product

Resources

About